Cogent Biosciences, Inc. COGT 深 沪
等待开盘 08-10 09:30:00 美东时间
42.39
+0.590
+1.41%
华盛通- 最 高43.39
- 今 开42.25
- 成交量 178.66万股
- 最 低 39.195
- 昨 收 41.80
- 总市值 270.10万
- 52周最高 43.73
- 市盈率 静 --
- 换手率 2803.94%
- 52周最低 11.53
- 委 比 -81.68%
- 总股本 6.37万
- 历史最高 43.73
- 量 比 0.84
- 振 幅 10.04%
- 历史最低 1.10
- 每 手 1
- 风险率 10.65%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Cogent Biosciences Files New Drug Application To FDA For Bezuclastinib In Advanced Systemic Mastocytosis
Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today announced it has submitted its New Drug Application (NDA) to the U.S.
06-30 20:04
Cogent Biosciences Q4 EPS $(0.61) Misses $(0.53) Estimate
Cogent Biosciences (NASDAQ:COGT) reported quarterly losses of $(0.61) per share which missed the analyst consensus estimate of $(0.53) by 15.97 percent. This is a 577.78 percent decrease over losses of $(0.09) per share
02-18 05:58
Why Is Pfizer Stock Rising Tuesday?
Pfizer Inc. (PFE) shares are trading higher on Tuesday, as the stock benefits from a price target increase at Cantor Fitzgerald. The firm raised its target to $27 from $24, providing a catalyst for the pharmaceutical giant even as the broader Healthcare sector declined 1.6% during the session.
01-28 02:20
Needham Reiterates Hold on Cogent Biosciencesto Hold
Needham analyst Ami Fadia reiterates Cogent Biosciences (NASDAQ:COGT) from Hold to Hold.
2025-12-09 00:17
Gold Jumps Over 2%; Dole Shares Gain After Q3 Results
U.S. stocks traded higher midway through trading, with the Nasdaq Composite gai...
2025-11-11 01:01
S&P 500 Surges 1%; Tyson Foods Posts Upbeat Earnings
U.S. stocks traded higher this morning, with the S&P 500 gaining around 1% ...
2025-11-10 22:43
守护“塞外粮仓”
（来源：中国银行保险报网） 转自：中国银行保险报网 □徐丹妮 本报记者 赵修彬 作为国家重要商品粮基地和农畜产品供应基地，内蒙古自治区赤峰市凭借北纬41°黄金农...
2025-10-20 08:17
开拓保险业绿色发展新天地
（来源：中国银行保险报网） 转自：中国银行保险报网 编者按： 近年来，践行“两山”理念已成为全民共识和自觉行动，成为生态文明和美丽中国建设的生动实践。金融监管总...
2025-08-15 07:41
Cogent Biosciences Secures up to $400 Million in Non-Dilutive Financing
Cogent Biosciences secures $400M debt facility to support growth, including 2026 launch of bezuclastinib and upcoming pivotal trial results in 2025.
2025-06-11 12:00
Cogent Biosciences Announces Participation in the Jefferies Global Healthcare Conference
Cogent Biosciences announced its presentation at the Jefferies Global Healthcare Conference on June 5, 2025. The event will be live-streamed on its website, with a replay available within two hours and archived for 30 days. Additionally, the company granted equity awards to five new employees under its 2020 Inducement Plan, totaling 127,000 shares of common stock with a four-year vesting schedule. Cogent is focused on developing precision therapies for genetically defined diseases.
2025-05-29 12:00
